ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Roche to pay Dicerna $200 million for hepatitis B virus RNAi therapy

by Ryan Cross
November 9, 2019 | APPEARED IN VOLUME 97, ISSUE 44

 

Roche will pay $200 million to license Dicerna Pharmaceuticals’ RNA interference (RNAi) drug candidate for hepatitis B virus (HBV). Dicerna could also earn up to $1.5 billion in future payments for the molecule, which is in a Phase I clinical trial. The program will complement Roche’s experimental small-molecule and antisense oligonucleotide HBV treatments. Other companies developing RNAi therapies for HBV include Johnson & Johnson and Vir Biotechnology.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment